EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Defining the role of systemic autoimmune markers in adult epilepsy: A focus on autoimmune‐associated epilepsy

I-Ting Lin iD, Chiehyu Shen, Chi-Ting Chung iD, Chang-Yu Edward Cheng, Pin-Yu Chen, Tun Jao

Epilepsia Open · 2025

DOI: 10.1002/epi4.70159 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Epilepsia Open, 2025. Verfasst von I-Ting Lin und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, National Taiwan University Hospital, Taipei, Taiwan. Hauptthemen laut MEDLINE: Epilepsy, Autoantibodies, Autoimmune Diseases. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Taiwan University Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Autoimmune mechanisms are a recognized cause of adult epilepsy, with immunotherapy offering etiology‐specific treatment. Autoimmune‐associated epilepsy is an emerging clinical entity, for which early diagnosis remains challenging and largely depends on neuronal antibody testing. This study investigates the utility of serum systemic autoantibodies as surrogate markers for positive neuronal antibodies and their potential in predicting epilepsy outcomes.

Methods

We retrospectively enrolled adult epilepsy patients, excluding those with prior autoimmune diseases. All patients had baseline laboratory data, including ESR, ANA, and anti‐ENA. Further immunological evaluations included serum or CSF studies for systemic or neuronal autoantibodies. We compared the prevalence of systemic autoantibodies, seizure patterns, and EEG characteristics across immune, other, and unknown etiological groups and assessed epilepsy outcomes based on autoimmune comorbidities and systemic autoantibody presence.

Results

Among 333 patients (immune = 12, other = 122, unknown = 199), autoimmune‐associated epilepsy showed higher rates of status epilepticus (41.7% vs. 0.5% vs. 2.5%, p < 0.001), multifocal epileptogenicity (41.7% vs. 9.1% vs. 8.2%, p < 0.01), ≥2 anti‐seizure medications (83.3% vs. 28.6% vs. 43.4%, p < 0.001), and a worse seizure outcome. Systemic autoantibodies were prevalent across subgroups (27.6%–41.7%), and autoimmune comorbidities were newly diagnosed in 5.5%–9.8% of cases, but no differences were observed across groups. The prevalence of antiphospholipid syndrome (2.1%) and Sjögren's syndrome (1.5%) was high in our study cohort. Neither autoimmune comorbidities nor systemic autoantibodies correlated with seizure types, EEG patterns, seizure frequency, number of ASMs, or outcomes. Significance Autoantibody testing contributes to unexpectedly high rates of new rheumatological diagnoses following epilepsy, often preceding systemic symptoms. However, systemic autoantibodies cannot reliably predict epilepsy characteristics or outcomes. Multifocal epileptogenicity on EEG and high seizure burden may be characteristic features in autoimmune‐associated epilepsy. These findings suggest that adult epilepsy patients should benefit from a tiered approach to immunological evaluation. Plain Language Summary Autoimmune causes of epilepsy are increasingly recognized, and some patients may benefit from immunotherapy in addition to standard anti‐seizure drugs. We retrospectively analyzed adult epilepsy patients by underlying cause and examined their clinical features, EEG findings, and blood tests for systemic autoantibodies. In our study, although these systemic autoantibodies were prevalent, they did not help predict seizure type, EEG pattern, or treatment outcome. However, we found that patients with seizure activity coming from several parts of the brain or frequent, hard‐to‐control seizures may have autoimmune‐associated epilepsy and could benefit from advanced immune evaluation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

EpilepsyAutoantibodiesAutoimmune DiseasesHumansFemaleMaleRetrospective StudiesMiddle AgedAdultBiomarkersElectroencephalographyAgedYoung Adult

Stichwörter der Autor:innen

Sjögren's syndromeadult epilepsyantiphospholipid syndromeautoantibodyautoimmune‐associated epilepsyneuronal antibody

Substanzen

AutoantibodiesBiomarkers

Autor:innen und Institutionen

  • Department of Neurology, National Taiwan University Hospital, Taipei, Taiwan.
  • Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
  • Department of Neurology, En Chu Kong Hospital, New Taipei City, Taiwan.
  • Department of Neurology, National Taiwan University Hospital, Hsin-Chu Branch, Hsinchu, Taiwan.
  • Epilepsy Center, National Taiwan University Hospital, Taipei, Taiwan.
  • Department of Neurology, National Taiwan University, Taipei, Taiwan.

ORCID-Profile: I-Ting Lin, Chi-Ting Chung

Förderung

  • National Taiwan University Hospital

Zitieren

APA

Lin, I. T., Shen, C., Chung, C. T., Cheng, C. E., Chen, P. Y., & Jao, T. (2025). Defining the role of systemic autoimmune markers in adult epilepsy: A focus on autoimmune‐associated epilepsy. Epilepsia Open. https://doi.org/10.1002/epi4.70159

Vancouver

Lin IT, Shen C, Chung CT, Cheng CE, Chen PY, Jao T. Defining the role of systemic autoimmune markers in adult epilepsy: A focus on autoimmune‐associated epilepsy. Epilepsia Open. 2025. doi:10.1002/epi4.70159

BibTeX
@article{Lin2025,
  author = {Lin, I-Ting and Shen, Chiehyu and Chung, Chi-Ting and Cheng, Chang-Yu Edward and Chen, Pin-Yu and Jao, Tun},
  title = {Defining the role of systemic autoimmune markers in adult epilepsy: A focus on autoimmune‐associated epilepsy},
  journal = {Epilepsia Open},
  year = {2025},
  doi = {10.1002/epi4.70159}
}
Kostenlos starten →